MRNA-0217/S001 Personalized Tumor Vaccine is under clinical development by Shanghai Xinpu BioTechnology and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MRNA-0217/S001 Personalized Tumor Vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MRNA-0217/S001 Personalized Tumor Vaccine overview
The vaccine candidate is under development for the treatment of advanced solid tumors and advanced pancreatic cancer. It is an mRNA vaccine.
Shanghai Xinpu BioTechnology overview
Shanghai Xinpu BioTechnology a biotechnology research company specialized in development and treatment of advanced solid tumors. The company is headquartered in Shanghai City, Shanghai, China.
For a complete picture of MRNA-0217/S001 Personalized Tumor Vaccine’s drug-specific PTSR and LoA scores, buy the report here.